LY96 and inflammatory bowel disease: Similarly, in a pediatric cohort of IBD patients receiving either infliximab or adalimumab, the main polymorphisms associated with a suboptimal drug concentration of infliximab were in the TLR2 and LY96 genes; interestingly, LY96 is a protein that acts as an enhancer of the lipopolysaccharide-TLR interaction, thus amplifying inflammatory stimuli via NF-κB.